Cerity Partners
IRMD icon

Cerity Partners’s iRadimed IRMD Stock Holding History

Cerity Partners’s Portfolio IRMD Stock Details IRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$295K Sell
3,087
-226
-7% -$20.6K ﹤0.01% 2808
2026
Q1 		$319K Buy
3,313
+634
+24% +$63.4K ﹤0.01% 2567
2025
Q4 		$261K Buy
+2,679
New +$230K ﹤0.01% 2490

Other funds holding IRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Copeland Capital Management Conshohocken, Pennsylvania $4.87B AUM 31.21% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cerity Partners's IRMD Position: Q2 2026 in Review

Cerity Partners reduced its iRadimed (IRMD) stake by 6.8% in Q2 2026, selling an estimated $20.6K and leaving 3,087 shares worth $295K. The position accounts for ﹤0.01% of the portfolio, ranked #2808.

Cerity Partners first reported a position in IRMD in Q4 2025 and has held it in 3 quarters since. The position peaked at $319K in Q1 2026. 214 funds tracked by Wall St. Rank hold IRMD as of Q2 2026.

  • Cerity Partners held 3,087 shares of iRadimed worth $295K as of Q2 2026.
  • Cerity Partners sold 226 iRadimed shares in Q2 2026, an estimated $20.6K.
  • iRadimed made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #2808 holding.
  • Cerity Partners first reported a position in iRadimed in Q4 2025 and has held it in 3 quarters since.
  • Cerity Partners's iRadimed position peaked at $319K in Q1 2026.
  • 214 funds tracked by Wall St. Rank held iRadimed as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.